International journal of urology : official journal of the Japanese Urological Association · 2025
Clinical Predictors of Fluoroquinolone-Resistant Escherichia coli in Transrectal Ultrasound-Guided Prostate Biopsy: Insights for Tailored Prophylaxis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Somoto Takatoshi, Utsumi Takanobu, Ishitsuka Naoki, Noro Takahide, Suzuki Yuta, Iijima Shota, Sugizaki Yuka, Oka Ryo, Endo Takumi, Kamiya Naoto, Shimizu Naomi, Hiruta Nobuyuki, Suzuki Hiroyoshi
Аннотация
OBJECTIVES: To identify clinical predictors of fluoroquinolone-resistant Escherichia coli colonization and evaluate their usefulness in guiding personalized antibiotic prophylaxis for patients undergoing transrectal ultrasound-guided prostate biopsy.
METHODS: A retrospective analysis was conducted on 539 patients who underwent biopsy between January 2015 and March 2023 at a high-volume referral center. Clinical data, including demographic, biochemical, and pathological parameters, were extracted. Patients were stratified into high- and low-risk groups based on the Japanese Urological Association's risk classification. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of fluoroquinolone-resistant E. coli.
RESULTS: Fluoroquinolone-resistant E. coli was detected in 17.1% of patients. The prevalence increased significantly over time, from 14.1% in the earlier period (2015-2019) to 20.9% in the later period (2019-2023) (p = 0.04). Multivariate analysis identified elevated C-reactive protein greater than 0.09 mg/dL and the use of steroid or immunosuppressive therapy as independent predictors of fluoroquinolone-resistant E. coli. In high-risk patients, elevated HbA1c greater than 5.9% was also a significant predictor. Notably, patients with fluoroquinolone-resistant flora had significantly lower rates of prostate cancer detection, particularly among low-risk individuals (52.1% vs. 75.7%, p < 0.01).
CONCLUSIONS: Elevated C-reactive protein and immunosuppressive therapy are strong clinical predictors of fluoroquinolone-resistant E. coli colonization. These factors should be integrated into pre-biopsy assessment to guide selective rectal swab testing and tailor prophylactic strategies, thereby enhancing patient safety and reducing antibiotic resistance.
METHODS: A retrospective analysis was conducted on 539 patients who underwent biopsy between January 2015 and March 2023 at a high-volume referral center. Clinical data, including demographic, biochemical, and pathological parameters, were extracted. Patients were stratified into high- and low-risk groups based on the Japanese Urological Association's risk classification. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of fluoroquinolone-resistant E. coli.
RESULTS: Fluoroquinolone-resistant E. coli was detected in 17.1% of patients. The prevalence increased significantly over time, from 14.1% in the earlier period (2015-2019) to 20.9% in the later period (2019-2023) (p = 0.04). Multivariate analysis identified elevated C-reactive protein greater than 0.09 mg/dL and the use of steroid or immunosuppressive therapy as independent predictors of fluoroquinolone-resistant E. coli. In high-risk patients, elevated HbA1c greater than 5.9% was also a significant predictor. Notably, patients with fluoroquinolone-resistant flora had significantly lower rates of prostate cancer detection, particularly among low-risk individuals (52.1% vs. 75.7%, p < 0.01).
CONCLUSIONS: Elevated C-reactive protein and immunosuppressive therapy are strong clinical predictors of fluoroquinolone-resistant E. coli colonization. These factors should be integrated into pre-biopsy assessment to guide selective rectal swab testing and tailor prophylactic strategies, thereby enhancing patient safety and reducing antibiotic resistance.